NPPA Fixes Retail Price of 65 New Drugs, Ceiling Price of 20 Formulations, Details

New Delhi: Through recent notifications, the National
Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and
Fertilizers, has fixed the maximum retail price of 65 new drugs, along with determining
the ceiling price for 13 scheduled formulations. Additionally, the Authority
has also revised the ceiling price for 7 formulations including WPI impact @0.00551% for the year 2024.

In exercise of the powers conferred by paragraphs 4, 6, 10,
11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O.
1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued
by the Government of India the Ministry of Chemicals and Fertilizers and in
supersession of the Order of the Government of India in the Ministry of
Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O.
1548(E) dated 26th March, 2024 in so far
as it relates to formulation packs mentioned in the table below, except in
respect of things done or omitted to be done before such supersession, the
National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby
fixes the price as specified in column (5) of the table herein below as ceiling
price exclusive of goods and services tax applicable, if any, in respect of the
Scheduled formulation specified in the corresponding entry in column (2) of the
said Table with the dosage form & strength and unit specified respectively
in the corresponding entries in columns (3) and (4) thereof:

TABLE

S. No

Medicine

Dosage Form and Strength

Unit

Ceiling Price (₹)

1

Anti-rabies immunoglobulin

Injection 150 IU/ml

1 ML

3,107.59

2

Anti-rabies immunoglobulin

Injection 300 IU/ml

1 ML

109.56

3

Measles vaccine

As licensed

Each vial of 0.5ml

50.20

4

Anti-tetanus immunoglobulin

As licensed (250 IU)

1 Vial

1,244.79

5

Anti-tetanus immunoglobulin

As licensed (500 IU)

1 Vial

1,875.75

6

Anti-tetanus immunoglobulin

As licensed (1000 IU)

1 Vial

2,684.19

7

BCG vaccine

As licensed

Each dose (0.10 ML)

8.01

8

Measles Rubella vaccine

As licensed

Each vial of 0.5ml

71.19

9

Amphotericin B Liposomal

Injection 50mg/vial

1 Vial

6,648.23

10

Amphotericin B Lipid

Injection 50mg/vial

1 Vial

1,887.75

11

Water for injection

Injection

Each pack (10 ml)

2.42

12

Budesonide + Formoterol (MDI)

400 mcg + 6 mcg

Per Metered Dose

3.37

13

Budesonide + Formoterol (MDI)

200 mcg + 6 mcg

Per Metered Dose

2.96

Revised Ceiling Prices Considering WPI Adjustment

A second notification revises ceiling price further, factoring in
the Wholesale Price Index (WPI) impact of 0.00551%.

In implementation of directions of review order issued by
the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control)
Order, 2013 vide order specified in column (7) of the table below and in
exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18
of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the
30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the
Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order of the Government of India in the Ministry of Chemicals and
Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date
specified in the Column (8) of the table, the National Pharmaceutical Pricing
Authority, hereby fixes/revises the price including WPI impact @0.00551% for
the year 2024 as specified in column (6) of the table herein below as ceiling
price exclusive of Goods and Services Tax applicable, if any, in respect of the
Scheduled formulation specified in the corresponding entry in column (2) of the
said Table with the dosage form & strength and unit specified respectively
in the corresponding entries in columns (3) and (4) thereof:

TABLE

S. No

Medicine

Dosage Form & Strength

Unit

Old Ceiling Price (₹)

Revised Price (₹)

Review Order and Date

Previous SO and Date

1

Thiamine

Injection 100 mg/ml

1 ml

22.59

26.70

31015/45/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 652)

2

Clarithromycin

Oral Liquid 125mg/5ml

1 ml

4.61

4.65

31015/38/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 151)

3

Lignocaine

Injection 2%

1 ml

1.04

1.14

31015/46/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 405)

4

Lignocaine

Topical forms 2-5%

1 gm/ml

1.13

1.08

31015/46/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 404)

5

Clarithromycin

Tablet 250 mg

1 tablet

23.89

24.06

31015/86/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 149)

6

Ascorbic Acid

Tablet 500 mg

1 tablet

1.48

1.54

31015/68/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 55)

7

Atorvastatin

Tablet 10 mg

1 tablet

4.94

4.97

31015/86/2023Pricing (04.10.2024)

1547(E) (26.03.2024, Sl. No. 59)

NPPA also notified the MRP for various antiviral, cardiology, antibiotic, anti-diabetic, and vitamin formulations. In exercise of the powers conferred by paragraphs 5, 11 and
15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the
30th May, 2013 and S. O. 5249(E) dated 11th November,
2022 issued by the Government of India in the Ministry of Chemicals and
Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter
referred as NPPA), hereby fixes, the price as specified in column (6) of the
Table herein below as the retail price, exclusive of Goods and Services Tax, if
any, in relation to the formulation specified in the corresponding entry in
column (2) of the said Table with the strength, unit and name of manufacturer
& marketing company, as specified in the corresponding entries in columns
(3), (4) and (5) thereof;

TABLE

S.

No.

Medicines

Strength

Unit

Manufacturer &

Marketing

Company

Retail

Price

(in Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1

Acebrophylline and

N-Acetylcysteine

Tablets

Each film coated tablet contains:

Acebrophylline 100 mg

N-Acetylcysteine Ph. Eur. 600 mg

1 Tablet

M/s Win Medicare

Pvt. Ltd./

M/s Modi-

Mundipharma Pvt.

Ltd.

14.31

2

Acyclovir SustainedRelease Tablets

Each uncoated sustained-release tablet contains: Acyclovir IP 1200mg

1 Tablet

M/s Rivpra

Formulation Pvt. Ltd. / M/s Mankind Pharma Ltd.

56.21

3

Atorvastatin &

Ezetimibe Tablets

Each film coated tablet contains:

Atorvastatin Calcium IP eq. to

Atorvastatin 40 mg

Ezetimibe IP 10 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt.

Ltd./ M/s Sun

Pharma

Laboratories

Limited

34.65

4

Atorvastatin &

Ezetimibe Tablets

Each film coated tablet contains:

Atorvastatin Calcium IP eq. to

Atorvastatin 40 mg

Ezetimibe IP 10 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Sun

Pharmaceutical

Industries Limited

34.65

5

Atorvastatin &

Ezetimibe Tablets

Each film coated tablet contains:

Atorvastatin Calcium IP eq. to

Atorvastatin 20 mg

Ezetimibe IP 10 mg

1 Tablet

M/s Sun Pharma

Laboratories

Limited/ M/s Sun

Pharmaceutical

Industries Limited

27.38

6

Atorvastatin &

Ezetimibe Tablets

Each film coated tablet contains:

Atorvastatin Calcium IP eq. to

Atorvastatin 20 mg

Ezetimibe IP 10 mg

1 Tablet

M/s Sun Pharma

Laboratories

Limited

27.38

7

Dispersible

Amoxycillin &

Potassium

Clavulanate Tablets

BP

Each uncoated dispersible tablet contains:

Amoxycillin Trihydrate IP eq. to

Amoxycillin 400 mg

Potassium Clavulanate Diluted IP eq. to
Clavulanic Acid 57 mg

1 Tablet

M/s Malik

Lifesciences Pvt.

Ltd./

M/s Micro Labs Ltd.

24.66

8

Bisoprolol Fumarate

and Amlodipine

tablets

Each film coated tablet contains:

Bisoprolol Fumarate IP 5 mg Amlodipine besylate IP eq. to

Amlodipine 5 mg

1 Tablet

M/s Dr. Miltons Laboratories Pvt.

Ltd./

M/s Aristo Pharmaceuticals Pvt. Ltd.

8.40

9

Bisoprolol Fumarate

and Amlodipine

tablets

Each film coated tablet contains:

Bisoprolol Fumarate IP 2.5 mg

Amlodipine besylate IP eq. to

Amlodipine 5 mg

1 Tablet

M/s Dr. Miltons Laboratories Pvt.

Ltd./

M/s Aristo Pharmaceuticals Pvt. Ltd.

6.32

10

Cefuroxime Axetil and Potassium clavulanate
Tablets

Each film coated tablet contains:

Cefuroxime Axetil IP eq. to

Cefuroxime 500 mg

Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg

1 Tablet

M/s Alps communication Pvt.

Ltd./

M/s Aristo Laboratories Pvt.

Ltd.

58.08

11

Cefuroxime Axetil &

Potassium

Clavulanate Tablets

Each film coated tablet contains:

Cefuroxime Axetil IP eq. to

Cefuroxime 500mg

Potassium Clavulanate Diluted IP eq. to
Clavulanic Acid 125mg

1 Tablet

M/s Innova Captab Limited /M/s Dr.

Reddy’s

Laboratories

Limited

58.08

12

Vitamin D3 Oral Drops

Each ml contains:

Cholecalciferol (Vitamin D3) IP 800 IU

1 ml

M/s Akums Drugs

& Pharmaceuticals Ltd./ M/s Alkem

Laboratories Ltd.

5.75

13

Cholecalciferol (Vitamin D3) oral solution

Each 5 ml contains:

Cholecalciferol IP (in nano droplet form) 60000IU

1 ml

M/s Ravenbhel

Healthcare Pvt.

Ltd./

M/s Aristo Laboratories Pvt.

Ltd.

18.93

14

Cholecalciferol (Vitamin D3) oral solution

Each 5 ml contains:

Cholecalciferol IP 60000IU

1ml

M/s Ravenbhel

Healthcare Pvt. Ltd./

M/s Macleods Pharmaceuticals Ltd.

20.23

15

Cilnidipine &

Metoprolol Succinate

(ER) Tablets

Each film coated bilayered tablet contains:

Cilnidipine 10mg

Metoprolol Succinate USP 23.75mg eq. to
Metoprolol Tartrate 25mg (in extended-release form)

1 Tablet

M/s Ravenbhel

Biotech / M/s Mankind Pharma Ltd.

9.91

16

Cilnidipine &

Metoprolol Succinate

(ER) Tablets

Each film coated bilayered tablet contains:

Cilnidipine 10mg

Metoprolol Succinate USP 47.5mg eq. to Metoprolol
Tartrate 50mg (in extended release form)

1 Tablet

M/s Ravenbhel

Biotech/ M/s Mankind Pharma Ltd.

11.02

17

Dextromethorphan

Hydrobromide,

Bilastine &

Phenylephrine

Hydrochloride Syrup

Each 5ml contains:

Dextromethorphan Hydrobromide

IP 10mg

Bilastine IP 3.3mg

Phenylephrine Hydrochloride IP

5mg

1ml

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s
Akumentis Healthcare Ltd.

1.17

18

Diclofenac Injection

IP

Each ml contains: Diclofenac
sodium IP 75 mg

1ml

M/s Nitin

Lifesciences Ltd /M/s Aristo Laboratories Pvt.

Ltd.

31.38

19

Esomeprazole and

Domperidone

Sustained Release capsules

Each hard gelatin capsule

contains:
Esomeprazole Magnesium IP eq. to Esomeprazole 40 mg (as enteric coated
pellets)

Domperidone Maleate IP eq. to Domperidone 30 mg
(sustained release)

1 Capsule

M/s Windlas

Biotech Ltd./

M/s Intas Pharmaceuticals Ltd.

12.39

20

Esomeprazole &

Domperidone

Capsules

Each hard gelatin capsule contains: Esomeprazole Magnesium

Trihydrate IP eq. to Esomeprazole

40 mg (as enteric coated pellets) Domperidone IP 30 mg (as sustained release pellets)

1 Capsule

M/s Pure & Cure Healthcare Pvt.

Ltd./

M/s German

Remedies

Pharmaceuticals Pvt. Ltd.

12.50

21

Etamsylate &

Tranexamic Acid

Tablets

Each film coated tablet contains:

Etamsylate BP 250 mg

Tranexamic Acid IP 250 mg

1 Tablet

M/s Skymap

Pharmaceuticals

Pvt. Ltd./ M/s

German Remedies Pharmaceuticals Pvt. Ltd.

19.59

22

Glimepiride IP,

Voglibose IP,

Metformin

Hydrochloride (SR) tablets

Each uncoated bilayered tablet contains:

Glimepiride IP 0.5 mg, Voglibose IP

0.2 mg, Metformin Hydrochloride IP (as sustained release form) 500 mg

1 Tablet

M/s Windlas

Biotech Limited/

M/s Intas Pharmaceuticals Ltd.

9.12

23

Gliclazide MR &

Metformin

Hydrochloride ER tablets

Each uncoated bilayered tablet contains:

Metformin Hydrochloride (in extended release
form) IP 500 mg Gliclazide (in modified release form) IP 30 mg

1 Tablet

M/s Unison

Pharmaceuticals

Pvt. Ltd

7.46

24

Gliclazide MR &

Metformin

Hydrochloride ER tablets

Each uncoated bilayered tablet contains:

Metformin Hydrochloride (in extended release
form) IP 500 mg Gliclazide (in modified release form) IP 60 mg

1 Tablet

M/s Unison

Pharmaceuticals

Pvt. Ltd

9.74

25

Glimepiride,

Voglibose IP,

Metformin

Hydrochloride IP (as sustained release form)
tablets

Each uncoated bilayered tablet contains:

Glimepiride IP 0.5mg

Voglibose IP 0.2mg

Metformin Hydrochloride IP 500mg

(as sustained release form)

1 Tablet

M/s Windlas

Biotech Ltd./

M/s Lupin Limited

9.12

26

Glimepiride,

Voglibose and

Metformin

Hydrochloride (ER) tablets

Each uncoated bi-layered tablet contains: Glimepiride IP 1mg, Voglibose IP 0.2mg and
Metformin

Hydrochloride IP 500mg (ExtendedRelease form)

1 Tablet

M/s Mascot Health

Series Pvt. Ltd./

M/s German

Remedies

Pharmaceuticals Pvt. Ltd.

11.62

27

Glimepiride,

Voglibose and

Metformin

Hydrochloride (ER) tablets

Each uncoated bi-layered tablets contains:

Glimepiride IP 2 mg, Voglibose IP

0.2mg and Metformin

Hydrochloride IP 500mg (ExtendedRelease form)

1 Tablet

M/s Mascot Health

Series Pvt. Ltd./

M/s German

Remedies

Pharmaceuticals Pvt. Ltd.

14.79

28

Itraconazole Capsules BP

Each hard gelatin capsule contains:

Itraconazole BP 50 mg

1 Capsule

M/s Pure and Cure Healthcare Pvt.

Ltd./

M/s Biological E.

Limited

11.51

29

Multivitamin &

Multimineral Drops

Each ml contains :

Cholecalciferol (as Stabilized)IP

200 IU

Pyridoxine HCl IP
0.5mg

Niacinamide IP 5mg

Cyanocobalamin IP 1mcg Sodium Selenite
Pentahydrate BP eq. to elemental Selenium 10 mcg Zinc Sulphate Monohydrate IP
eq. to elemental Zinc 2 mg

Manganese sulphate Monohydrate BP eq. to
elemental Manganese 3 mcg

Sodium molybdate dihydrate BP eq. to elemental
Molybdenum 1 mcg L-Lysine Hydrochloride IP 30 mg

Potassium Iodide IP eq. to elemental

Iodine 20 mcg

Biotin IP 5 mcg

Chromium Picolinate IP eq. to elemental Chromium
1 mcg

Myo-Inositol IP 10 mg

Beta Carotene Dispersion 2.5% 18 mg

1 ml

M/s Ordain Health Care Global Pvt.

Ltd. /

M/s Aristo
Pharmaceuticals Pvt. Ltd.

3.10

30

Pantoprazole & Cinitapride SR capsules

Each hard gelatin capsule
contains:

Pantoprazole Sodium IP eq. to Pantoprazole 40 mg (as enteric

coated tablet)

Cinitapride
Hydrogen tartrate eq. to Cinitapride (as Sustained release tablet)3 mg

1 Capsule

M/s Pure and Cure Healthcare Pvt. Ltd./

M/s Dr. Reddy’s

Laboratories Ltd.

24.82

31

Paracetamol &

Mefenamic Acid

Suspension

Each 5 ml contains:

Paracetamol IP 250 mg

Mefenamic Acid IP 100 mg

1 ml

M/s Tirupati

Medicare Ltd./

M/s Dr. Reddy’s

Laboratories

Limited

0.92

32

Paracetamol and

Mefenamic Acid

Suspension

Each 5 ml contains:

Paracetamol IP 125 mg

Mefenamic Acid IP 50 mg

1 ml

M/s Skymap

Pharmaceuticals

Pvt. Ltd./ M/s

German Remedies Pharmaceuticals Pvt. Ltd.

0.73

33

Paracetamol IP &

Mefenamic Acid

Suspension

Each 5 ml contains:

Paracetamol IP 125 mg

Mefenamic Acid IP 50 mg

1 ml

M/s Tirupati

Medicare Limited /

M/s Dr. Reddy’s

Laboratories

Limited

0.73

34

Riboflavin, Folic

Acid Niacinamide &

Lactic Acid Bacillus

Spores Tablets

Each uncoated tablet contains:

Riboflavin IP 10mg

Folic Acid IP 1.5mg

Niacinamide IP 100mg

Lactic Acid Bacillus Spores 60 million

1 Tablet

M/s Marine

Medicare Pvt. Ltd. /

M/s Nicholas

Healthcare Limited

4.25

35

Sodium
Alginate,

Sodium Bicarbonate,

Calcium Carbonate

Oral Suspension

Each 5 ml contains: Sodium

Alginate IP
250 mg

Sodium Bicarbonate IP 133.5 mg

Calcium Carbonate IP 80 mg

1 ml

M/s Windlas

Biotech Ltd./ M/s Biological E.

Ltd.

0.83

36

Tacrolimus Ointment

Composition:

Tacrolimus I.P. eq. to Anhydrous

Tacrolimus 0.1%w/w

1 gm

M/s Rivpra

Formulation Pvt.

Ltd./

M/s RPG Life Sciences Ltd.

35.64

37

Telmisartan &

Chlorthalidone

Tablets

Each uncoated tablet contains:

Telmisartan IP 40 mg

Chlorthalidone IP 12.5 mg

1 Tablet

M/s Skymap

Pharmaceuticals

Pvt. Ltd./ M/s

German Remedies Pharmaceuticals Pvt. Ltd.

11.59

38

Telmisartan &

Cilnidipine Tablets

Each film coated tablet contains:

Telmisartan IP 40 mg

Cilnidipine IP 10 mg

1 Tablet

M/s Skymap

Pharmaceuticals

Pvt. Ltd./ M/s

German Remedies Pharmaceuticals Pvt. Ltd.

11.11

39

Telmisartan &

Cilnidipine Tablets

Each film coated bilayered tablet contains:

Telmisartan IP 80 mg

Cilnidipine IP 10 mg

1 Tablet

M/s Macleods Pharmaceuticals Ltd.

16.10

40

Telmisartan &

Indapamide tablets

Each uncoated bilayered tablet contains:

Telmisartan IP 40mg

Indapamide IP 1.5mg (as sustained release)

1 Tablet

M/s Windlas

Biotech Ltd. /

M/s Eris

Lifesciences

Limited

13.25

41

Telmisartan,

Cilnidipine and Chlorthalidone tablets

Each film coated tablet contains:

Telmisartan IP 40 mg

Cilnidipine IP 10 mg

Chlorthalidone IP 12.50 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt.

Ltd./ M/s Torrent Pharmaceuticals Ltd.

15.15

42

Telmisartan,

Amlodipine and

Hydrochlorothiazide

Tablets

Each film coated tablet contains:

Telmisartan IP 40 mg

Amlodipine Besylate IP eq. to

Amlodipine 5 mg

Hydrochlorothiazide IP 12.5 mg

1 Tablet

M/s Skymap

Pharmaceuticals

Pvt. Ltd./ M/s

German Remedies Pharmaceuticals Pvt. Ltd.

11.00

43

Tranexamic Acid and Mefenamic Acid

tablets

Each film coated tablet contains:

Tranexamic Acid IP 500 mg

Mefenamic Acid IP 250 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./

M/s Pharmed

Limited

31.50

44

Dapagliflozin,

Glimepiride,

Metformin

Hydrochloride (extended release) tablets

Each film coated bilayered tablet contains:

Dapagliflozin Propanediol USP eq.

to Dapagliflozin 10 mg,

Glimepiride IP 1 mg,

Metformin Hydrochloride (extended

release) IP 500 mg

1 Tablet

M/s Mascot Health

Series Pvt. Ltd./

M/s Aristo Pharmaceuticals Pvt. Ltd.

12.42

45

Dapagliflozin,

Glimepiride,

Metformin

Hydrochloride (extended release) tablets

Each film coated bilayered tablet contains:

Dapagliflozin Propanediol USP eq. to
Dapagliflozin 10 mg,

Glimepiride IP 2 mg,

Metformin
Hydrochloride IP 500 mg (extended release)

1 Tablet

M/s Mascot Health

Series Pvt. Ltd./

M/s Aristo Pharmaceuticals Pvt. Ltd.

12.42

46

Dapagliflozin,

Glimepiride,

Metformin

Hydrochloride (extended release) tablets

Each film coated bilayered tablet contains:

Dapagliflozin Propanediol USP eq. to
Dapagliflozin 10 mg,

Glimepiride IP 1 mg,

Metformin Hydrochloride (extended

release) IP 500 mg

1 Tablet

M/s Mascot Health

Series Pvt. Ltd./

M/s Alembic Pharmaceuticals Ltd.

12.42

47

Dapagliflozin,

Glimepiride,

Metformin

Hydrochloride (extended release) tablets

Each film coated bilayered tablet contains:

Dapagliflozin Propanediol USP eq. to
Dapagliflozin 10 mg, Glimepiride IP 2 mg,

Metformin
Hydrochloride

(extended release) IP 500 mg

1 Tablet

M/s Mascot Health

Series Pvt. Ltd./

M/s Alembic Pharmaceuticals Ltd.

12.42

48

Sitagliptin,

Dapagliflozin and

Metformin

Hydrochloride

(extended release)

Tablets

Each film coated bilayered tablet contains: Sitagliptin phosphate monohydrate IP eq. to
Sitagliptin

100mg

Dapagliflozin propanediol USP eq. to
Dapagliflozin 10mg

Metformin hydrochloride IP (as extended release
form) 1000mg

1 Tablet

M/s Mascot Health

Series Pvt. Ltd/

M/s FDC limited

18.21

49

Sitagliptin,

Dapagliflozin and

Metformin

Hydrochloride

(extended release)

Tablets

Each film coated bilayered tablet contains: Sitagliptin phosphate

monohydrate IP eq. to Sitagliptin

100mg

Dapagliflozin propanediol USP eq. to
dapagliflozin 10mg

Metformin hydrochloride IP (as extended release
form) 500mg

1 Tablet

M/s Mascot Health

Series Pvt. Ltd/

M/s FDC Limited

17.26

50

Sitagliptin,

Pioglitazone and

Metformin

Hydrochloride

(sustained release)

Tablets

Each film coated bilayered tablet contains: Sitagliptin phosphate

monohydrate IP eq. to Sitagliptin

100mg

Pioglitazone Hydrochloride IP eq. to

Pioglitazone 15mg

Metformin hydrochloride IP (as sustained release
form) 500mg

1 Tablet

M/s Akums Drugs

& Pharmaceuticals

Ltd./

M/s Cadila Pharmaceuticals Ltd.

14.15

51

Sitagliptin,

Pioglitazone and

Metformin

Hydrochloride

(sustained release)

Tablets

Each film coated bilayered tablet contains: Sitagliptin phosphate

monohydrate IP eq. to Sitagliptin

100mg

Pioglitazone Hydrochloride IP eq. to

Pioglitazone 15mg

Metformin hydrochloride IP (as sustained release
form) 1000mg

1 Tablet

M/s Akums Drugs

& Pharmaceuticals

Ltd./

M/s Cadila Pharmaceuticals Ltd.

15.43

52

Sitagliptin &

Metformin

Hydrochloride tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate

IP eq. to Sitagliptin 50 mg Metformin
Hydrochloride IP 500 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./

M/s Blue Cross Laboratories Pvt.

Ltd.

9.00

53

Sitagliptin &

Metformin

Hydrochloride tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate

IP eq. to Sitagliptin 50 mg

Metformin Hydrochloride IP 1000 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt.

Ltd./

M/s Blue Cross Laboratories Pvt.

Ltd.

9.87

54

Vildagliptin (SR) &

Metformin

Hydrochloride (SR) tablets

Each film coated bilayered tablet contains:

Vildagliptin IP 100 mg (as sustained release
form)

Metformin Hydrochloride IP 500 mg (as sustained
release form)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s
Primus

Remedies Pvt. Ltd.

10.24

55

Vildagliptin (SR) &

Metformin

Hydrochloride (SR) tablets

Each film coated bilayered tablet contains:

Vildagliptin IP 100 mg (as sustained release
form)

Metformin Hydrochloride IP 1000 mg (as sustained
release form)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s
Primus

Remedies Pvt. Ltd.

11.55

56

Linagliptin &

Metformin

Hydrochloride (ER) tablets

Each film coated bilayered tablet contains:

Linagliptin 5 mg

Metformin hydrochloride IP (as extended release
form) 500 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd.

/M/s Eris

Lifesciences

Limited

10.68

57

Ceftazidime and Avibactam Powder for concentrate
Solution for Infusion

Each vial contains:

Sterile Ceftazidime Pentahydrate IP eq. to
Anhydrous Ceftazidime 2 gm

Sterile Avibactam sodium eq. to

Avibactam 0.5 gm

1 vial

M/s GMH

Organics/

M/s Aurobindo

Pharma Limited

1422.21

58

Ceftriaxone, Disodium Edetate and Sulbactam
Powder for Solution for Infusion

Each vial contains:

Ceftriaxone Sodium IP eq. to

Ceftriaxone 1000mg

Sulbactam Sodium IP eq. to

Sulbactam 500mg

Disodium Edetate IP 37mg

1 vial

M/s Alkem Health

Science (A Unit of

Alkem Laboratories

Ltd.) / M/s Alkem

Laboratories Ltd

515.57

59

Ceftriaxone, Disodium Edetate and Sulbactam
Powder for Solution for Infusion

Each vial contains:

Ceftriaxone Sodium IP eq. to

Ceftriaxone 2000mg

Sulbactam Sodium IP eq. to

Sulbactam 1000mg

Disodium Edetate IP 74mg

1 vial

M/s Alkem Health

Science (A Unit of

Alkem Laboratories

Ltd.) / M/s Alkem

Laboratories Ltd

1036.60

60

Empagliflozin &

Metformin

Hydrochloride

Tablets

Each film coated tablet contains: Empagliflozin 5 mg

Metformin
Hydrochloride IP 500 mg

1 Tablet

M/s Cipla Ltd.

8.50

61

Empagliflozin &

Metformin

Hydrochloride

Tablets

Each film coated tablet
contains:

Empagliflozin 12.5 mg

Metformin
Hydrochloride IP 500 mg

1 Tablet

M/s Cipla Ltd.

12.00

62

Ferrous Bisglycinate, Folic Acid,

Zinc Bis-glycinate &

Vitamin B12

(Cyanocobalamin)

Tablets

Each film coated tablet contains:

Ferrous Bis-glycinate eq. to

Elemental Iron 60mg

Zinc Bis-glycinate eq. to Elemental

Zinc 15mg

Folic Acid IP 1mg

Vitamin B12 IP 15mcg

(Cyanocobalamin)

1 Tablet

M/s Windlas

Biotech Limited / M/s Biological E. Limited

8.17

63

Iron tonic with

Vitamin B12 and

Folic Acid

Each 5ml contains:

Ferric Ammonium Citrate IP 80mg

Folic Acid IP 0.166mg

Vitamin B12 IP 1mcg

1 ml

M/s Aagya Biotech

Pvt. Ltd. / M/s J. B.

Chemicals & Pharmaceuticals Ltd.

0.45

64

Atorvastatin and Ezetimibe tablets

Each film coated tablet contains: Atorvastatin Calcium IP equivalent

to Atorvastatin 80 mg, Ezetimibe IP 10mg

1 Tablet

M/s Windlas

Biotech ltd./ M/s Intas pharmaceuticals Ltd.

50.00

65

Famotidine, Calcium

Carbonate &

Magnesium

Hydroxide Chewable

Tablets

Each chewable tablet contains:

Famotidine IP 10mg

Calcium Carbonate IP 800mg

Magnesium Hydroxide IP 165mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s
Akumentis Healthcare Ltd.

5.30

Additionally, the notifications mentioned that manufacturers
of scheduled formulations selling their products above the specified ceiling
price, including applicable Goods and Services Tax (GST), are required to
revise their prices downward to comply with the ceiling price set by the
National Pharmaceutical Pricing Authority (NPPA). If the manufacturers already
sell these products at a price lower than the ceiling, they must maintain their
current Maximum Retail Price (MRP) in line with paragraph 13(2) of the Drugs
(Prices Control) Order (DPCO), 2013. Additionally, GST can only be added to the
ceiling price if it has actually been paid or is payable to the government.

The determination of the ceiling price must adhere to the
provisions outlined in paragraph 11 of the DPCO, 2013. Manufacturers are
required to issue updated price lists (Form-V) from the date of the
notification and submit these to the NPPA via the Integrated Pharmaceutical
Database Management System (IPDMS), as well as to State Drug Controllers and
dealers. Retailers and dealers are obligated to display the price list and any
supplementary updates in a conspicuous location within their business premises
to ensure easy access for consumers.

If a manufacturer introduces a new drug with dosage or
strength specified in the schedule, they must apply for prior price approval
from the NPPA, following the guidelines in Schedule II of the DPCO, 2013.
Regular reporting is also mandatory, with quarterly returns detailing
production, import, and sales of scheduled formulations to be submitted via
Form-III. In cases of production discontinuation, manufacturers must notify the
NPPA at least six months in advance through Form-IV.

Non-compliance with these regulations will result in
penalties, including the repayment of overcharged amounts with interest. Such
violations fall under the purview of the DPCO, 2013, and the Essential
Commodities Act, 1955. Finally, this notification supersedes any prior price
orders for the listed formulations, ensuring uniform implementation of the
revised ceiling prices.

Powered by WPeMatico

Early detection model for pancreatic necrosis improves patient outcomes

A new prediction model for infected pancreatic necrosis (IPN) in patients with acute pancreatitis (AP) offers a groundbreaking approach to improving patient outcomes. Developed by a team of researchers across eight Chinese hospitals, the model harnesses five early clinical indicators—respiratory rate, temperature, serum glucose, calcium, and blood urea nitrogen (BUN)—to identify high-risk patients within 24 hours of hospital admission.

Powered by WPeMatico

AI model achieves high accuracy in skin cancer detection

Led by Aliyu Tetengi Ibrahim and his team at Ahmadu Bello University, a study published in Data Science and Management on November 2, 2024, introduces an innovative AI model that could revolutionize the way dermatologists detect skin cancer.

Powered by WPeMatico

Hypersensitive strain sensor enables real-time stroke monitoring

A research team led by Prof. Seung-Kyun Kang from the Department of Materials Science and Engineering at Seoul National University has developed a strain sensor with record-breaking sensitivity in collaboration with researchers from Dankook University, Ajou University, and Purdue University.

Powered by WPeMatico

Discovery of norovirus replication hubs offers new antiviral targets

Human norovirus, a positive-strand RNA virus that is the leading cause of viral gastroenteritis accounting for an estimated 685 million cases and approximately 212,000 deaths globally per year, has no approved vaccines or antivirals.

Powered by WPeMatico

First dual chamber leadless pacemaker implanted in a child

UC Davis Director of Pediatric Electrophysiology Dan Cortez has set another world record: He is the first to implant a dual chamber leadless pacemaker in a child. His case report was published this week in the journal Pacing and Clinical Electrophysiology.

Powered by WPeMatico

Ex-ECL Medical Superintendent Jailed for 4 years, Fined Rs 30000 in Bribery Case

Asansol: A special CBI court in Asansol has sentenced Dr Sunil Kumar Singh, the former Medical Superintendent (ENT) of Eastern Coalfields Limited (ECL), to four years of imprisonment and imposed a fine of ₹30,000 in a bribery case dating back to 2009.

According to a UNI report, the special judge of the court in Asansol on Thursday awarded Dr Sunil Kumar Singh, then Medical Superintendent (ENT) of ECL’s Central Hospital, Kalla, Bardhaman, to four years of Imprisonment with a fine of Rs. 30,000 in a case of bribery.

The Central Bureau of Investigation had registered the case on February 16,2009 against Dr. Sunil Kumar Singh, accused of accepting a bribe of Rs. 400 for issuing a medical certificate to the complainant.  

Also Read:Doctor Suicide Case: Delhi Court to sentence convicted AAP MLA on March 17

After the completion of the investigation, a chargesheet was filed by the CBI against the accused on 25.08.2009, news agency UNI reported.

The court, after trial, found the accused guilty and sentenced him accordingly, sources added.  

Medical Dialogues had earlier reported that the Sealdah court in Kolkata granted bail to Sandip Ghosh, the former principal of RG Kar Medical College and Hospital, and Abhijit Mondal, the former officer-in-charge of Tala police station, in connection with the rape and murder case of a woman trainee doctor on August 9.

While Mondal was accused of alleged delay in filing of FIR in the rape and murder of the on-duty doctor at R G Kar Hospital on August 9, Sandip Ghosh was accused of tampering with evidence in the case.   

Also Read:Assam Doctor Assault 2021 Case: 12 people sentenced to 10 years of imprisonment

Powered by WPeMatico

NMC warns Medical Colleges to Remit Fees Timely before closing date

New Delhi: Taking note of the high volume of rush on behalf of medical colleges to pay/remit fees through the link generated during form fill-up, the Postgraduate Medical Education Board (PGMEB) of the National Medical Commission (NMC) has advised the institutes to apply timely before the closing date.

Writing to the Directors/Principals/Deans of all medical colleges/institutes under the Commission, the NMC Secretary Prof B Srinivas has also mentioned that the payments can be remitted in normal Banking timings on all days but on closing date payment shall be accepted till 02:00 PM only.

The Commission has also warned that the onus of any technical failures/glitches of payment on closing time would only be on the applicant. Therefore, the Commission has advised the medical colleges/institutes to remit payment sufficiently before the closing timing.

In the communication addressed to the heads of the medical colleges/institutes, NMC Secretary Prof Srinivas mentioned, “It is aware that all Medical colleges/Institutes are required to pay/remit fee through link generated during filling form. It is noted that despite giving sufficient timeline including extension in filing application, there is high volume of rush on closing date. This may sometime fail the payment due to overload/glitches.”

“All the stakeholders are advised to file application timely before the closing date by shedding any lackadaisical approach and acting with high agility in filing application,” the Apex Medical Commission further added.

Also Read: NMC Invites Applications for New PG Medical Courses, setting up standalone PG institutes, intake increase for 2025-2026, here are complete details

Advising the medical colleges to remit payment sufficiently before the closing timing to avoid any technical glitches of payment, the Commission stated, “It may be noted that payment can be remitted in normal Banking timings on all days but on closing date payment shall be upto 14:00 hrs (i.e. 2:00 p.m) only. Further, for any technical failure/glitches of payment on closing time i.e. 2 PM of closing date onus would be on applicant only. So, to avoid that, they may remit payment sufficiently before the closing timing.”

Earlier this year, while inviting applications for starting new post-graduate medical courses in an established medical institution, establishing a new post-graduate medical institute (standalone PG institute) and increase of seats in existing PG medical courses for the Academic Year 2025-2026, NMC had notified about the required fee for these applications.

FEE FOR VARIOUS APPLICATIONS/PROCESSES EFFECTIVE FROM 17TH NOVEMBER 2023-

S. No.

Particulars

Amount of fees

1.

Starting of PG courses in Medical colleges/Establishment of standalone PG institution

Rs 5 lakhs +18% GST per course up to 4 seats & additional Rs 1 lakh/seat for more than 4 seats

2

Increase of admission capacity of PG courses

Rs 5 lakhs + 18% GST per course up to 4 seats & additional Rs 1 lakh/seat for more than 4 seats.

3.

Verification of any additional information asked for or for evaluation of any corrected deficiencies if asked to do so.

Rs 75, 000 + 18% GST

4.

Appeal fee

Rs. 50,000 + 18% GST

Meanwhile, the fee for submitting the Annual Declaration Report for PG Medical Courses is Rs 50,000 plus 18% GST for each PG medical course on the designated NMC portal by 22.11.2024.

To view the NMC notice, click on the link below:

https://medicaldialogues.in/pdf_upload/nmc-timing-of-remitting-fees-265764.pdf

Also Read: PG medical courses: NMC further Extends Deadline to submit Annual Declaration, to impose fine after 22 November

Powered by WPeMatico

DNB Post Diploma Admissions 2024: NBE Releases Stipend Guidelines, Check All Details here

New Delhi- The National Board of Examination (NBE) invited applications for Participation in the Centralized Merit Based Counselling for Admission to Post Diploma DNB Courses 2024 Admission Session. NBE has also released an information bulletin detailing the Stipend guidelines

The counselling process will be held till December 24th.

STIPEND GUIDELINES:

 NBEMS has published its updated Stipend Guidelines vide notice dated 09.09.2024.

 Paying stipend to the NBEMS trainees by the accredited hospitals/medical institutions is compulsory.

 According to the NBEMS stipend policy, the hospital shall have to pay the NBEMS trainees a BASIC stipend in accordance to any of the following applicable categories:

Basic Stipend prescribed by the NBEMS: 

For the first year of the Post MBBS DNB (Broad Specialty) Courses, the minimum stipend prescribed by the NBEMS is Rs 35,000/-, for the second year, it is Rs 37,000/- and for the third year, it is 39,000/-, taking the total cost to Rs 1,11,000/-.

POST MBBS DNB (BROAD SPECIALITY)

S.NO

YEAR OF DNB TRAINING

STIPEND (IN INR) PER MONTH

1

First Year

Rs 35,000/-

2

Second Year

Rs 37,000/-

3

Third Year

Rs 39,000/

TOTAL

Rs 1,11,000/-

For the first year of the Post Diploma DNB (Broad Specialty) Courses, the minimum stipend is Rs 37,000/- and for the second year, it is Rs 39,000/-, taking the total cost to Rs 76,000/-.

POST DIPLOMA DNB (BROAD SPECIALITY)

S.NO

YEAR OF DNB TRAINING

STIPEND (IN INR) PER MONTH

1

First Year

37,000/-

2

Second Year

39,000/

TOTAL

76,000/-

For the first year of the 2 Year Diploma Post MBBS Diploma, the minimum stipend prescribed by the NBEMS is Rs 35,000/- and for the second year, it is Rs 37,000/-, taking the total cost to Rs 72,000.

2 YEAR DIPLOMA POST MBBS – BROAD SPECIALITY COURSES :

S.NO

YEAR OF DNB TRAINING

STIPEND (IN INR) PER MONTH

1

First Year

35,000/-

2

Second Year

37,000/-

TOTAL

Rs 72,000

For the first year of the DrNB (Super Specialty) Courses, the stipend is Rs 41,000/-, for the second year, it is Rs 43,000/- and for the third year, it is 45,000/- taking the total cost to Rs 1,29,000/-.

DrNB (SUPER SPECIALTY)

S.NO

YEAR OF DNB TRAINING

STIPEND (IN INR) PER MONTH

1

First Year

Rs 41,000/-

2

Second Year

43,000/-

3

Third Year

45,000/-

TOTAL

Rs 1,29,000/-

For the first year of the FNB Courses, the stipend is Rs 41,000/- and for the second year, it is Rs 43,000/-, taking the total cost to Rs 84,000/-.

FNB COURSES

S.NO

YEAR OF DNB TRAINING

STIPEND (IN INR) PER MONTH

1

First Year

Rs 41,000/-

2

Second Year

Rs 43,000/-

TOTAL

Rs 84,000/-

Meanwhile the “basic stipend according to state government policy” for MBBS 02 year Diploma courses in nine broad specialities is interpreted according to the different states, which is mentioned below-

S.NO

CATEGORIES OF STATES

FOR NBEMS DIPLOMA COURSES

1

States where the stipend to MD/MS and DM/MCh trainees of State Govt Medical Colleges is paid as a consolidated sum (without any break-up of basic pay and allowances).

The consolidated sum paid to MD/MS trainees of State Govt Medical Colleges.

2

States where the stipend paid to MD/MS and DM/MCh trainees of State Govt Medical Colleges is structured as a “Basic pay plus various allowances” and paid as per recommendations of 7th CPC.

Pay level 10 of 7th CPC

The 1st & 2nd Year Diploma Trainees should be treated at par with the 1st & 2nd Year DNB Trainees for Trainees.

Cell 1 & 2 of pay level 10 in the Pay matrix of 7th CPC correspond to 1st & 2nd year of training respectively.

* This does not include any kind of allowances as may be paid to MD/MS candidates in respective states. It is at liberty to the accredited hospitals to pay any allowances over and above the minimum sum prescribed by NBEMS.

Stipend for NBEMS trainees in Railway, ESIC, Central PSUs, Central Autonomous & Central Government Hospitals / Medical Institutions:

The Railway, ESIC, Central PSUs, Central Autonomous & Central Government hospitals / medical institutions shall have to pay the NBEMS trainees a basic stipend as prescribed by the NBEMS at Sr. no. (i) above or basic stipend mentioned as under (whichever is higher):

For DNB / Diploma (Broad

Specialty) Trainees

For DrNB (Super Specialty) & FNB

Trainees

Basic Stipend as prescribed by the

NBEMS

OR

The Basic Pay * paid to Nonacademic Junior Residents in the

concerned Central Govt. hospital

OR

Pay level 10 of 7th CPC*

{Cell 1, 2 and 3 of pay level

10 in pay matrix of 7th CPC

correspond to first, second

and third year of training

respectively}

(Equal basic pay * where IDA

pattern is followed. IDA pay pattern

is followed in PSUs)

Whichever in above is higher

Basic Stipend as prescribed by the

NBEMS

OR

The Basic Pay * paid to Nonacademic Senior Residents in the

concerned Central Govt. hospital

OR

Pay level 11 of 7th CPC*

{Cell 1, 2 and 3 of pay

level 11 in pay matrix of

7th CPC correspond to

first, second and third year

of training respectively}

(Equal basic pay * where IDA

pattern is followed. IDA pay

pattern is followed in PSUs)

Whichever in above is higher

* This does not include any kind of allowances as may be paid by the respective authority / hospitals. It is at liberty to the accredited hospitals to pay any allowances over and above the basic pay

 4th, 5th& 6th year trainees of a Direct 6 year NBEMS courses shall be paid stipend equal to 1st , 2nd & 3rd year trainees of a Super specialty course respectively provided that they clear the DNB Part-I Examination.

 In order to maintain the parity to basic stipend guidelines, the rate of stipend needs to be periodically revised by the respective hospitals / medical institutions in accordance to the revision of stipend made by the respective State Governments (for Sr. no. ii) or by the Central Government/Authorities (for Sr. no. iii) from time to time.

 NBEMS accredited hospitals are at liberty to pay NBEMS trainees a monthly stipend more than the prescribed stipend.

 It is also desirable that the hospital provides accommodation to their trainees in addition to their stipend. However, the hospital shall not reduce the stipend of the trainees in lieu of providing accommodations.

The Centralized Online Merit Based counselling for admission to DNB (Post Diploma) 2024 admission session shall be conducted by NBEMS as per the schedule given below:

S.No. COUNSELING PROCESS Schedule
FIRST ROUND SECOND ROUND
I Registration for Counseling 3 rd to 6th December, 2024 (till 05:00 PM) No new Registration
ii Filling up option/ choices of available seats 3 rd to 6th December, 2024 (till 05:00 PM) 16th to 18th December, 2024 (till 05:00 PM)
iii. Processing of Allotment 7 th to 8 th December, 2024 19th December, 2024
iv Result of Allotment 9 th December, 2024 20th December, 2024
v Payment of First Year Course Fee 9th to 12th December, 20th to 24th December, 2024 (till 05:00 PM)
VI Physical Joining at the allotted hospita 2024 (till 05:00 PM) 20th to 24th December, 2024 (till 05:00 PM)

To view the official Notice, Click here : https://medicaldialogues.in/pdf_upload/nbems20241496063122jpg-262576.pdf

Powered by WPeMatico

Delhi AIIMS, Blockchain For Impact join hands to boost biomedical innovation

New Delhi: In a bid to boost the biomedical research and innovation in the public health sector, the All India Institute of Medical Sciences (AIIMS) Delhi on Friday announced a collaboration with Blockchain For Impact (BFI).

According to an IANS report, as per the Memorandum of Understanding (MoU) signed by the two organisations, BFI will support a project exploring genetic and epigenetic factors to identify potential marks for recurrent urinary tract infections.

Recurrent urinary tract infections (rUTI) represent a major healthcare and economic burden with a significant impact on patient’s morbidity and quality of life.

The project, led by Dr Sarita Mohapatra, Additional Professor, Department of Microbiology at AIIMS Delhi is funded under the BFI-BIOME Medical INI Grant Programme, which supports Medical Institutes of National Importance (INIs) through the Blockchain For Impact Biomedical Virtual Network (BFI-BIOME).

Also Read:AIIMS signs MoU with Wipro GE Healthcare to set up AI health innovation hub

This network, created by BFI, aims to foster multisectoral collaboration, support upstream and deep science research, and drive innovation to strengthen biomedical research in India.

AIIMS Delhi is home to 25 clinical departments and four super-specialty centers. Its research initiatives have made significant contributions to combating infectious diseases such as leprosy, malaria, and tuberculosis, as well as non-communicable diseases like diabetes, and more.

The partnership with AIIMS Delhi aligns perfectly with BFI’s mission to accelerate transformative healthcare solutions through cutting-edge biomedical innovation.

“At AIIMS New Delhi, we are committed to advancing healthcare innovation through cutting-edge research and technology. The support from the BFI-BIOME Medical INI Grant Programme enables us to explore new frontiers in medical science, empowering our faculty and researchers to make transformative contributions to global healthcare,” said Dr M Srinivas, Director of AIIMS Delhi.

“The BFI-BIOME initiative represents a paradigm shift by fostering collaboration between leading biomedical researchers, clinicians, and innovators to pioneer the next generation of health interventions. Partnering with AIIMS Delhi is a step in the right direction for us. It reinforces our commitment to strengthening the healthcare ecosystem in India,” added Sandeep Nailwal, the visionary founder of BFI, news agency IANS reported.

This partnership between AIIMS Delhi with BFI marks a pivotal milestone in the BFI-BIOME Network Programme’s ongoing efforts to advance biomedical research and innovation in India.

By fostering innovation and equitable access, BFI aims to create a transformative healthcare ecosystem that addresses the nation’s most pressing medical challenges.

Also Read:10 kg tumour involving multiple organs successfully removed at AIIMS Delhi

Powered by WPeMatico